Prescription concentrations start at 1% and can go significantly higher
FDA has accepted the NDA for an oral formulation of Novo Nordisk A/Ss Wegovy (semaglutide) in treating obesity
[5] Despite presenting its product as an alternative to other medications that work to treat obesity, the advertisement obscures the fact that Hims weight loss medications are unapproved, compounded products that have not been subject to clinical testing or FDA scrutiny and pose a higher risk to patients than FDA-approved drugs. [6] Most alarmingly, the commercial makes no mention of side-effects, warnings, or the potentially serious risks posed by any semaglutide product
N Engl J Med 314(23):14941497 Rocha JF, Vaz-Da-Silva M, Nunes T, Igreja B, Loureiro AI, Bonifcio MJ, Wright LC, Falco A, Almeida L, Soares-Da-Silva P (2012) Single-dose tolerability, pharmacokinetics, and pharmacodynamics of etamicastat (BIA 5453), a new dopamine -hydroxylase inhibitor, in healthy subjects
GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones produced by the gut in response to nutrient ingestion
